Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of ramucirumab plus FOLFIRI versus placebo plus FOLFIRI in previously treated metastatic colorectal cancer
2010-021037-32Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in metastatic colorectal adenocarcinoma (mCRC) and colorectal cancer (CRC) comparing FOLFIRI plus ramucirumab with FOLFIRI plus placebo (2 arms). Primary endpoint: overall survival. Started Nov 2010; status: completed.
02
Drugs
ramucirumab
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)colorectal cancer (CRC)
Beyond the preview
Go deeper on 2010-021037-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021037-32.